Neuroblastic tumors, arising from the sympathetic nervous system, present a clinical conundrum due to their heterogeneous nature and varied biological behavior. Current diagnostic modalities, while effective in locating and partially characterizing these tumors, often fall short in differentiating live tumor cells from necrotic or non-viable tissue. This differentiation is critical, as residual viable cells post-surgery can lead to recurrence and treatment resistance, underscoring the need for real-time, intraoperative assessment tools.

Enter indocyanine green fluorescence, a near-infrared dye with a proven track record in medical imaging and surgical guidance. Traditionally used for vascular and lymphatic mapping, ICG’s fluorescence properties enable it to highlight tissue perfusion and viability dynamically. The study by You and Chen leverages these properties, exploring how ICG fluorescence can serve as a biomarker for tissue viability specifically within neuroblastic tumors.

The methodology underpinning this research involved administering ICG to pediatric patients diagnosed with neuroblastic tumors prior to surgical intervention. During surgery, specialized imaging devices captured the fluorescence emitted by the tumor tissues upon excitation by near-infrared light. The intensity and distribution of this fluorescence were then meticulously analyzed to map viable regions against areas showing diminished or absent fluorescence, suggestive of non-viable or necrotic tissue.

Findings were remarkable. Viable neuroblastic tumor segments exhibited robust, uniform fluorescence, correlating strongly with histopathological assessments confirming cellular integrity and metabolic activity. Conversely, areas lacking fluorescence corresponded to necrotic zones, fibrosis, or non-functional tumor regions. This clear delineation provides surgeons with a dynamic visual map, enhancing the accuracy of tumor resections and minimizing inadvertent removal of healthy tissues.

The implications extend beyond operative precision. Real-time differentiation allows oncologists to tailor adjuvant therapies more effectively, concentrating on regions harboring residual viable tumor cells that may evade complete surgical excision. Such targeted therapeutic approaches could translate into improved survival rates and reduced treatment-related morbidities.

Mechanistically, the efficacy of ICG fluorescence in this context is rooted in its cellular uptake and retention, which depend heavily on local blood flow and cellular metabolism. Viable tumor cells maintain active vasculature and metabolic pathways enabling uptake, whereas necrotic or non-functional tissue lacks these capabilities, resulting in diminished fluorescence signals. This biological basis validates ICG’s role as a functional marker rather than merely an anatomical one.

Moreover, the nondestructive nature of fluorescence imaging means it can be seamlessly integrated into existing surgical workflows without added patient risk. The technology employs safe doses of ICG, which has a well-documented safety profile, particularly useful in pediatric populations where minimization of intervention-related risks is paramount.

Challenges remain, however, in universalizing this technique. Tissue depth, heterogeneous tumor environments, and variability in vascularization can influence fluorescence intensity and interpretation. The researchers acknowledge the need for standardized imaging protocols and advanced image-processing algorithms to enhance diagnostic accuracy and reproducibility.

Future directions proposed include integrating ICG fluorescence imaging with other modalities such as intraoperative ultrasound or MRI to construct comprehensive, multimodal maps of tumor viability. This synergy could further empower surgical teams, providing layered data to guide excision margins with unprecedented confidence.

The potential for ICG fluorescence also sparks interest in its application to other pediatric solid tumors with similar diagnostic hurdles. Expanding the research scope might reveal a wider spectrum of indications where this technology augments conventional histopathological techniques, shaping a new era of fluorescence-guided oncology surgery.

In parallel, ongoing research is investigating the pharmacokinetics of ICG in different pediatric tumor types, optimizing dosage and timing to maximize imaging outcomes. Personalized protocols tailored to specific tumor biology and patient characteristics could become the norm, ushering in precision medicine’s promise in surgical oncology.

This breakthrough aligns with a broader trend in cancer treatment emphasizing real-time assessment, minimal invasiveness, and maximal efficacy. Fluorescence-guided surgery represents a paradigm shift, moving away from reliance on static imaging and delayed pathology toward dynamic, in situ decision-making that could dramatically improve patient prognoses.

The study by You and Chen arrives at a critical juncture, offering a practical, implementable solution to a longstanding clinical challenge. As their findings gain traction, we may anticipate rapid adoption across surgical oncology centers worldwide, coupled with iterative technological enhancements fueled by interdisciplinary collaboration.

Taken together, the deployment of indocyanine green fluorescence imaging in differentiating viable from non-viable neuroblastic tumor tissue is a testament to the innovative spirit driving pediatric cancer research. It exemplifies how rethinking established tools through novel applications can yield transformative outcomes, underscoring the vital interplay between scientific ingenuity and clinical practice.

For families confronting the daunting reality of neuroblastic tumors, this technique heralds hope for more effective, less risky interventions. It stands as a beacon of progress, illuminating pathways to better survival and quality of life for some of the most vulnerable patients.

This pioneering work confirms that the future of pediatric oncology lies not only in discovering new drugs but also in refining how we visualize, understand, and tackle cancer at the surgical front line. Indocyanine green fluorescence, once an ancillary method, now emerges center stage as a critical ally in the fight against childhood neuroblastoma.

As the medical community embraces these revelations, sustained interdisciplinary research will be essential to optimize technology, validate clinical outcomes, and expand applications. Together, such efforts promise to solidify fluorescence-guided surgery as a new standard, transforming pediatric cancer care into a more precise and hopeful endeavor.

Subject of Research: Differentiating viable from non-viable neuroblastic tumors using indocyanine green fluorescence imaging.

Article Title: Indocyanine green fluorescence in differentiating viable from non-viable neuroblastic tumors.

Article References: You, J., Chen, Ht. Indocyanine green fluorescence in differentiating viable from non-viable neuroblastic tumors. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05090-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-026-05090-5

Neuroblastoma’s aggressive clinical course is frequently linked to amplification of the MYCN oncogene, a critical genetic alteration serving as both a prognostic marker and a therapeutic target. Despite this knowledge, the role of polymorphisms—variations in the DNA sequence—in the MYCN gene that do not necessarily amplify the gene but may affect its function or expression has remained largely unexplored, especially within homogenous ethnic cohorts. The study’s focus on Chinese Han children from Jiangsu Province offers a distinct genetic background to elucidate these relationships, which could guide personalized treatments and risk stratification in neuroblastoma patients.

The researchers executed a meticulously designed case-control study involving 402 children diagnosed with neuroblastoma and 473 matched healthy controls. By interrogating four specific single nucleotide polymorphisms (SNPs)—rs57961569 G>A, rs9653226 T>C, rs13034994 A>G, and rs60226897 G>A—within the MYCN locus, the study provided robust statistical analyses to examine correlations between these variants and neuroblastoma susceptibility. Utilizing odds ratios along with 95% confidence intervals enabled the team to quantify how strongly each polymorphism might contribute to cancer risk, factoring in intricate genetic and environmental interactions.

Among the four polymorphisms analyzed, all demonstrated significant associations with neuroblastoma susceptibility, indicating that these genetic variants could serve as markers for identifying high-risk individuals. Particularly compelling were findings from stratified analyses focusing on rs13034994 A>G and rs60226897 G>A. These variants showed heightened influence in certain subpopulations, suggesting the presence of gene-environment interplay or modifier genes that may amplify or mitigate risk in specific demographic or clinical contexts. Such stratification is pivotal in honing the predictive accuracy of genetic testing and could revolutionize early screening protocols in high-incidence regions.

A critical dimension of the study involved survival analysis based on MYCN expression levels. The data convincingly linked elevated MYCN expression with poor prognosis among high-risk neuroblastoma patients, consistent with previous literature highlighting the gene’s oncogenic potency. Intriguingly, patients exhibiting reduced MYCN expression had significantly better survival outcomes, underscoring the gene’s dual role as both a biomarker and a mechanistic driver of tumor aggressiveness. This insight supports therapeutic strategies targeting MYCN expression regulation as an avenue for improving patient prognoses.

The complexity of neuroblastoma’s genetic landscape encompasses not only gene amplification but also subtle polymorphic variations that may influence gene regulation, protein function, and downstream oncogenic pathways. This study elucidates that common polymorphisms within MYCN can modulate neuroblastoma risk, prompting a reevaluation of existing models that primarily focus on gene amplification alone. Incorporating polymorphic data into risk assessment frameworks could offer more individualized and precise prognostic predictions, especially in ethnically diverse populations where genetic architectures differ markedly.

The implications of these findings extend into clinical practice, particularly in oncology and pediatric care, where early risk prediction and tailored interventions remain paramount. Screening for MYCN polymorphisms could emerge as a complementary tool alongside standard diagnostic procedures, enabling identification of susceptible individuals before tumor manifestation or during early disease stages. Such proactive approaches have the potential to transform clinical outcomes by facilitating timely initiation of targeted therapies and stringent monitoring.

Moreover, the confirmation of MYCN polymorphisms as susceptibility factors in a Chinese population enriches the global understanding of neuroblastoma genetics. It highlights the necessity of population-specific research, given the substantial genetic diversity across ethnic groups that influence cancer susceptibility. This recognition could catalyze similar investigations in other regions and ethnicities, gradually building a comprehensive panorama of neuroblastoma genetics that is inclusive and applicable worldwide.

From a molecular biology perspective, the polymorphisms identified may affect MYCN gene regulation by altering promoter activity, transcription factor binding sites, or mRNA stability. Future mechanistic studies are warranted to decode how these variants influence MYCN expression dynamics and downstream oncogenic signaling. Such molecular insights could unveil novel drug targets or intervention points, providing adjunctive strategies to conventional chemotherapies or emerging immunotherapeutics.

The study’s design and methodology illustrate a rigorous approach, combining genetic epidemiology with molecular biology to unravel a complex trait. Utilizing a sizable cohort and robust statistical metrics strengthens the credibility and generalizability of the findings. However, the authors prudently acknowledge the necessity for larger-scale, multi-centric, and longitudinal studies to validate these associations and evaluate their functional consequences across diverse populations and clinical stages.

In addition to genetic investigations, integrating genomic data with environmental exposures, lifestyle factors, and epigenetic modifications could enrich understanding of neuroblastoma pathogenesis. The interaction between inherited genetic predispositions and exogenous factors may be pivotal in dictating disease onset and progression, warranting comprehensive, interdisciplinary research frameworks moving forward.

This groundbreaking work represents a seminal contribution to pediatric oncology and genetic epidemiology. By elucidating the intricate relationship between MYCN polymorphisms and neuroblastoma susceptibility in a defined Chinese demographic, it lays the foundation for precision medicine approaches that are genetically informed. It underscores the transformative potential of genetic research not only in unraveling disease mechanisms but also in enhancing clinical decision-making and personalized patient care.

The study also exemplifies the growing imperative to tailor cancer research to specific populations, embracing genetic heterogeneity as a critical dimension in disease modeling. Such endeavors empower healthcare systems to devise culturally and genetically sensitive interventions, ultimately improving survival rates and quality of life for vulnerable pediatric patients worldwide.

In conclusion, the association of MYCN gene polymorphisms with neuroblastoma susceptibility propels the field toward refined prognostic tools and targeted therapies. The observed genotype-phenotype correlations represent a paradigm shift from broad oncogene amplification models to nuanced genetic variability frameworks, illuminating novel avenues for research and clinical translation. This study encourages a sustained commitment to large-scale, well-designed genetic investigations that will unravel the enigmatic biology of neuroblastoma and foster breakthroughs in combatting this devastating childhood cancer.

Subject of Research: The association between MYCN gene polymorphisms and susceptibility to neuroblastoma in Chinese children.

Article Title: Association between MYCN gene polymorphisms and neuroblastoma susceptibility: a case-control study in Chinese children from Jiangsu Province.

Article References: Liu, J., Zhang, M., Ouyang, Y. et al. Association between MYCN gene polymorphisms and neuroblastoma susceptibility: a case-control study in Chinese children from Jiangsu Province. BMC Cancer 25, 892 (2025). https://doi.org/10.1186/s12885-025-14310-w

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14310-w